Ahuja Parmeet 4

What Happened
Parmeet Ahuja, Chief Financial Officer of MaxCyte, received a grant/award for 375,000 derivative shares on March 30, 2026. The filing reports an acquisition price of $0.00, so no cash was paid at grant. This is an award (not a sale) and does not represent an open-market purchase.

Key Details

• Transaction date: March 30, 2026; filing date (Form 4): April 10, 2026 (appears to be filed after the standard 2-business-day window).
• Award: 375,000 derivative shares; reported acquisition price $0.00; reported value $0 per the Form 4.
• Vesting (footnote): 25% vests on March 30, 2027; the remaining 75% vests in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No indication in the filing that shares were sold or immediately exercised—this is a grant subject to future vesting.

Context
This is a compensation award to an executive rather than an open-market purchase or sale. Such awards are common for retention and incentive purposes; vesting schedules mean the shares become available over time only if the executive remains employed. The filing date suggests the Form 4 was submitted after the typical 2-business-day reporting window, which is notable for compliance tracking but does not by itself indicate trading intent.